Source: France Soir

The Citizen Collective analyzed the mortality figures in India following the COVID seroprevalence survey for the province of Delhi. The Collective then compared them against the French figures. The result is final. With a strategy based on early treatment which includes hydroxychloroquine, Delhi has half the mortality rate despite contamination five times higher than in France.

Some mainstream media [1] have relayed very interesting information about COVID contaminations in India: 56% of the population of Delhi has developed anti-body covid so all this portion of the population has been contaminated by SARS-COV- 2.

As usual, analysis of these particularly interesting figures is sadly lacking in these media. 
It is the duty of the Citizen Collective to fill this gap.

With such a rate of contamination, we are faced with a scenario of collective quasi-immunity managed with a broad prescription of early and prophylactic treatment based on hydroxychloroquine [2]. 

A mortality analysis is informative on the effectiveness of such a treatment strategy.

COVID-19 TREATMENT PROTOCOLS – Government of India Ministry of Health and Family Welfare Directorate General of Health Services

To carry out this work we are based on the site which feeds a reference site for global data namely:

From the statistics page reserved for the province of Delhi  : we distinguish the following elements:

– Population of Delhi province: 19,814,000

– Covid deaths in Delhi: 10,879

From the numbers above, we can calculate the following metrics: 

Contaminated population (Total population x 56%) = 11,095,840
Mortality per million inhabitants (Deaths x million / Population) = 549
Lethality (Deaths / Contaminated population) = 0.1% or 1 per thousand

In the light of these figures, we can draw several interesting conclusions:

With a contamination rate of 56%, mortality is 549 people per million inhabitants. Last December, the Institut Pasteur estimated the rate of the French population to be contaminated at 11.3% [1]. Mortality in France is 1200 [2] people per million inhabitants. 

The population of Delhi is five times more contaminated with mortality more than two times lower compared to France.

The case fatality rate with early treatment in Delhi, which is 0.1%, is close to the rate estimated by Professor Raoult in the case of early treatment.

In light of these findings, shouldn’t the French government fundamentally change the current health policy?

There are of course many other factors (demographic, environmental, economic, and social …) that come to qualify this spotlight. But we believe that this factor, if it does not explain everything on its own, is of major importance in the differences observed by this comparison and that therefore health policy in France should be focused on early treatment, instead of being focused on measures of deprivation and restriction of freedoms.

[1] .html
[3] -the-population-has-been-infected-in-each-region-of-france-9235455.php

Additional references: 
In India, the mystery of low mortality from coronavirus  (Euronews)
Coronavirus: How did India become the second nation with the highest number of cases?  (RTBF)

Related: Journal of Medicine Says HCQ + Zinc Reduces COVID Deaths


HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Melbourne doctors urge officials to consider hydroxychloroquine, ivermectin in fight against COVID-19

Facebook Oversight Board admits Facebook was wrong to censor information about Hydroxychloroquine

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »